|Articles|September 1, 1999

September 1999
Volume 5
Issue 9

Selective Contracting and Patient Outcomes: A Case Study of Formulary Restrictions for Selective Serotonin Reuptake Inhibitor Antidepressants

Author(s)Dan A. Streja, MD, Rita L. Hui, PharmD, Elani Streja

Download PDF: Selective Contracting and Patient Outcomes: A Case Study of Formulary Restrictions for Selective Serotonin Reuptake Inhibitor Antidepressants

Articles in this issue

about 27 years ago

Article

Was the Decreasing Trend in Hospital Mortality from Heart Failure Attributable to Improved Hospital Care? The Oregon Experience, 1991-1995

about 27 years ago

Article

The Changing Healthcare Market and How It Has Influenced the Treatment of Cardiovascular Disease - Part I

about 27 years ago

Article

The Changing Healthcare Market: Outlook for the Future of Cardiovascular Disease Treatment - Part II

about 27 years ago

Article

Is a Third-Trimester Antibody Screen in Rh+ Women Necessary?

about 27 years ago

Article

Patient Factors Related to the Odds of Receiving Prevention Services in Veterans Health Administration Medical Centers

about 27 years ago

Article

Innovative Healthcare for Chronically Ill Older Persons: Results of a National Survey

about 27 years ago

Article

Office-Based Surgery and Cost Avoidance in an Obstetrics and Gynecology Residency Program

about 27 years ago

Article

Drug Therapy of Allergic Rhinitis

about 27 years ago

Article

Rethinking Formulary Strategy: Management and Measurement Considerations

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Predicting GLP-1 Discontinuation From Pharmacy Claims

ByAayush Sisodia, MSHI, BDS

Published: August 6th 2026 | Updated: August 31st 2026

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

ByThomas W. Martens, MD,Bimal V. Patel, PharmD, MS,Sharon M. Wang, PharmD, MS,Laurel H. Messer, PhD, MPH, RN, CDCES, BC-ADM,Jordan E. Pinsker, MD,Daniel C. Malone, PhD, RPh,Miranda R. Polin, MS, BS,Diana I. Brixner, PhD, RPh,Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES,Osagie Ebekozien, MD, MPH

July 23rd 2026

Geographical Access to Preferred Pharmacies in Medicare Part D

ByPinka Chatterji, PhD,Yiran Han, PhD,Chun-Yu Ho, PhD

July 22nd 2026

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

ByEmily A. Gadbois, PhD,Jennifer Bunker, MPH,Marguerite Daus, PhD, RN,Jamie M. Smith, PhD, RN,Emily Buss, MSN, RN,Christine D. Jones, MD, MS,Kali S. Thomas, PhD, MA

July 16th 2026

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

Selective Contracting and Patient Outcomes: A Case Study of Formulary Restrictions for Selective Serotonin Reuptake Inhibitor Antidepressants

Articles in this issue

Related Content

Predicting GLP-1 Discontinuation From Pharmacy Claims

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

Geographical Access to Preferred Pharmacies in Medicare Part D

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Trending on AJMC

Tozorakimab Curbs Multiple COPD Inflammatory Pathways, ERS Data Show

Fragmented Care, Financial Strain, Gender Gaps Define Life With COPD

AI Model Flags Colorectal Cancer on Routine Noncontrast CT Scans

FDA Approves Camizestrant for ER+, HER2– mBC With ESR1 Mutations

Tozorakimab Cuts COPD Exacerbations Up to 34% in Phase 3 Trials